Tesamorelin withdrawal findings

Fat returning after withdrawal

In the 52-week tesamorelin program, continued treatment sustained a reduction in visceral fat, the fat around internal organs. Fat reaccumulated when treatment stopped. The participants were adults with HIV-associated abdominal fat accumulation.

I regard that return as one of the study’s most useful findings. It changes the practical question from whether fat can be reduced to how a benefit is maintained, for whom and with what continuing burden. A final visit during treatment would leave that question hanging.

Tesamorelin’s FDA-approved purpose is reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Approval covers that specific condition. The evidence here does not establish an ordinary weight-loss or anti-aging treatment for the general population.

Fat measured on a scan

A six-month randomized trial in 50 adults with HIV receiving antiretroviral treatment reported a visceral-fat treatment effect of −42 square centimeters. That is the difference in change between the tesamorelin and placebo groups. A scan measures the area in an abdominal slice; kilograms on a scale measure something else. Liver fat also fell in that trial.

The meta-analysis of five randomized trials found a mean visceral-fat difference of −27.71 square centimeters, with reductions in trunk and liver fat and an increase in lean body mass. Lean body mass includes water and other tissues as well as muscle; I hesitate to describe that whole gain as muscle.

The HIV-associated condition remains in the result every time those figures travel. Replacing it with a general claim about belly fat removes the very population that supplied the evidence.

Hormone stimulation: safety findings

Tesamorelin prompts the pituitary gland to release growth hormone in pulses. The liver then produces more IGF-1, a growth factor. The short study of 13 healthy men found increased growth hormone and IGF-1 over two weeks, without a clear change in fasting glucose or insulin-stimulated glucose uptake. Its brief duration leaves long-term safety open.

Growth-hormone stimulation makes the safety questions substantial. Active cancer is a contraindication to the approved medicine. Years of elevated IGF-1 and changes in blood sugar require attention; the trials cannot settle every uncommon or late harm. Tesamorelin is also prohibited in sport because of its growth-hormone action.

The NIH LiverTox assessment regards clinically apparent liver injury from tesamorelin as unlikely. The combined trial review found no recurring pattern of serious harms attributed to the treatment. I welcome that reassurance within its observation period, while leaving rare events and longer exposure on the agenda.

This is a different proposition from semaglutide’s serious-illness trials. The fat findings answer a particular question in adults living with HIV, and the return after withdrawal deserves a place beside the reduction.